Risperidone in the management of disruptive behavior disorders

Journal of Child and Adolescent Psychopharmacology

Volumn 16, Issue 4, 2006, Pages 379-392

  Pandina, Gahan J ^a,d   Aman, Michael G ^b   Findling, Robert L ^c  

^a Medical Affairs Division   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; PLACEBO; PSYCHOSTIMULANT AGENT; RISPERIDONE; SEROTONIN 2A ANTAGONIST;

ADOLESCENT DISEASE; AGGRESSION; AKATHISIA; AMENORRHEA; ANGER; ANXIETY; AUTISM; AUTOMUTILATION; BODY WEIGHT; CHILD GROWTH; CHILD PSYCHIATRY; CHILDHOOD DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONDUCT DISORDER; COUGHING; DEPRESSION; DISEASE EXACERBATION; DISRUPTIVE BEHAVIOR; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEVER; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; INCREASED APPETITE; MENSTRUATION DISORDER; MENTAL INSTABILITY; METABOLIC DISORDER; MOOD DISORDER; MOTOR DYSFUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPPOSITIONAL DEFIANT DISORDER; PARKINSONISM; PHARYNGITIS; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; RHINITIS; SEDATION; SEXUAL MATURATION; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; SYMPTOM; TARDIVE DYSKINESIA; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; FOLLOW-UP STUDIES; HUMANS; LONG-TERM CARE; PILOT PROJECTS; RISPERIDONE; TREATMENT OUTCOME;

EID: 33750601586     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.16.379     Document Type: Review

References (44)

1. Ad-Dab'bagh Y, Greenfield B, Milne-Smith J, Freedman H: Inpatient treatment of severe disruptive behaviour disorders with risperidone and milieu therapy. Can J Psychiatry 45:376-382, 2000.
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 156:1686-1696, 1999.
3. Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Ghuman JK, Lindsay RL: Acute and long-term safety and tolerability of risperidone in children with autism. J Child and Adolesc Psychopharmacol 15:869-884, 2005.
4. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, Risperidone Disruptive Behavior Study Group: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346, 2002.
5. Aman MG, Singh NN, Stewart AW, Field CJ: Psychometric characteristics of the aberrant behavior checklist. Am J Ment Defic 89:492-502, 1985.
6. Aman MG, Tasse MJ, Rojahn J, Hammer D: The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Res Dev Disabil 17:41-57, 1996.
7. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
8. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association, 1994.
9. Biederman J, Mick E, Johnson MA, Faraone SV, Aleardi M, Spencer T, Wozniak J: A prospective open-label treatment trial of risperidone monotherapy in children and adolescents with bipolar disorder. Miami Beach (Florida), 50th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, October 14-19, 2003.
10. Bossie CA, Pandina G, Zhu Y, Gharabawi G: Risk of movement disorders is low in pediatric patients treated with risperidone. Phoenix (Arizona), 44th Annual Meeting of the New Clinical Drug Evaluation Unit, June 1-4, 2004.
11. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT: A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62:239-248, 2001.
12. Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van Dongen S, Risperidone Disruptive Behavior Study Group: Risperidone in children with disruptive behavior disorders and subaverage intelligence: A 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 44:64-72, 2005.
13. Czobor P, Volavka J, Meibach RC: Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 15:243-249, 1995.
14. De Deyn PP, Katz IR: Control of aggression and agitation in patients with dementia: Efficacy and safety of risperidone. Int J Geriatr Psychiatry 15(suppl 1):S14-S32, 2000.
15. Dunbar F, Kusumakar V, Daneman D, Schulz M: Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry 161:918-920, 2004.
16. Farrington DP: The Twelfth Jack Tizard Memorial Lecture. The development of offending and antisocial behaviour from childhood: Key findings from the Cambridge Study in Delinquent Development. J Child Psychol Psychiatry 360:929-964, 1995.
17. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B, Risperidone Disruptive Behavior Study Group: Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161:677-684, 2004.
18. Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C: Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362-1369, 2003.
19. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL: A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509-516, 2000.
20. Fisman S, Steele M: Use of risperidone in pervasive developmental disorders: A case series. J Child Adolesc Psychopharmacol 6:177-190, 1996.
21. Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencer TJ, Kim GS, Shapiro S: Risperidone treatment for juvenile bipolar disorder: A retrospective chart review. J Am Acad Child Adolesc Psychiatry 38:960-965, 1999.
22. Glass AR: Gynecomastia. Endocrinol Metab Clin North Am 23:825-837, 1994.
23. Guy W: ECDEU Assessment Manual for Psychopharmacology. Rockville (Maryland), National Institute of Mental Health, 1976.
24. Hellings JA, Zarcone JR, Crandall K, Wallace D, Schroeder SR: Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 11:229-238, 2001.
25. Horrigan JP, Barnhill LJ: Risperidone and explosive aggressive autism. J Autism Dev Disord 27:313-323, 1997.
26. Kay SR, Wolkenfeld F, Murrill LM: Profiles of aggression among psychiatric patients. I. Nature and prevalence. J Nerv Ment Dis 176:539-546, 1988.
27. Kemph JP, DeVane CL, Levin GM, Jarecke R, Miller RL: Treatment of aggressive children with clonidine: Results of an open pilot study. J Am Acad Child Adolesc Psychiatry 32:577-581, 1993.
28. Kuperman S, Schlosser SS, Kramer JR, Bucholz K, Hesselbrock V, Reich T, Reich W: Developmental sequence from disruptive behavior diagnosis to adolescent alcohol dependence. Am J Psychiatry 158:2022-2026, 2001.
29. Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, Findling RL, Fisman S, Greenhill LL, Huss M, Kusumakar V, Pine D, Taylor E, Tyano S. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): Clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14:11-28, 2004.
30. Lindsay RL, Leone S, Aman MG: Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders. Clin Pediatr (Phila) 43:437-444, 2004.
31. Marshburn EC, Aman MG: Factor validity and norms for the aberrant behavior checklist in a community sample of children with mental retardation. J Autism Dev Disord 22:357-373, 1992.
32. Martin A, Landau J, Leebens P, Ulizio K, Cicchetti D, Scahill L, Leckman JF: Risperidone-associated weight gain in children and adolescents: A retrospective chart review. J Child Adolesc Psychopharmacol 10:259-268, 2000.
33. Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, McDougle CJ, Tierney E, Chuang S, Vitiello B: Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 161:1125-1127, 2004.
34. Masi G, Cosenza A, Mucci M, Brovedani P: Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 40:1206-1214, 2001.
35. Moretti MM, Emmrys C, Grizenko N, Holland R, Moore K, Shamsie J, Hamilton H: The treatment of conduct disorder: Perspectives from across Canada. Can J Psychiatry 42:637-648, 1997.
36. Pandina G, Bilder R, Harvey PD, Keefe R, Aman M, Gharabawi G: Risperidone and cognitive function in children with disruptive behavior disorders. Miami Beach (Florida), 50th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, October 14-19, 2003.
37. Rydelius PA: Alcohol-abusing teenage boys. Testing a hypothesis on the relationship between alcohol abuse and social background factors, criminality and personality in teenage boys. Acta Psychiatr Scand 68:368-380, 1983.
38. Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486-487, 1982.
39. Schreier HA: Risperidone for young children with mood disorders and aggressive behavior. J Child Adolesc Psychopharmacol 8:49-59, 1998.
40. Schur SB, Sikich L, Findling RL, Malone RP, Crismon ML, Derivan A, Macintyre JC, Pappadopulos E, Greenhill L, Schooler N, Van Orden K, Jensen PS: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: A review. J Am Acad Child Adolesc Psychiatry 42:132-144, 2003.
41. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A, Risperidone Conduct Study Group: Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036, 2002.
42. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34, 2002.
43. Van Bellinghen M, De Troch C: Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 11:5-13, 2001.
44. Vanden Borre R, Vermote R, Buttiens M, Thiry P, Dierick G, Geutjens J, Sieben G, Heylen S: Risperidone as add-on therapy in behavioural disturbances in mental retardation: A double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 87:167-171, 1993.